Novel therapies, including endothelin receptor antagonists, sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, and APOL1‐targeted therapies, are being explored for their potential to reduce proteinuria and protect against glomerular damage in patients with FSGS and diabetic nephropathy [38, 39, 40]. This evidence concerns the gene SLC5A2 and focal segmental glomerulosclerosis.